 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Approval announced by Kyowa Kirin, Ardelyx Collaboration Partner Ardelyx to receive $30 million from Kyowa Kirin in milestone and license amendment payments and $5 million from HealthCare Royalty...

Tenapanor for Hyperphosphatemia Approved in Japan

Over the last three days, A.I.dvisor has detected that ARDX's AroonUp green line (see chart) is above 70, while the AroonDown red line is below 30. When the green line goes above 70 while the red...

Ardelyx (ARDX, $3.95) Aroon Indicator entered an Uptrend on September 22, 2023.

Ardelyx (ARDX, $4.17) Aroon Indicator entered an Uptrend on September 18, 2023.

This is a Bearish indicator signaling ARDX's price could decline from here. Traders may explore shorting the stock or put options...

Ardelyx (ARDX, $4.17) Moving Average Convergence Divergence (MACD) Histogram turned negative on September 18, 2023

This indicator may be signaling that ARDX's price has further to drop, since it moved below its price 14 days ago. Traders may consider selling the stock, shorting the stock, or exploring put options...

Ardelyx (ARDX, $4.17) entered Downtrend as Momentum indicator drops below 0 level on Sep 18, 2023

Investors in Ardelyx Inc (ARDX) saw new options become available this week, for the November 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ARDX...

First Week of November 17th Options Trading For Ardelyx (ARDX)

ARDX's total volume now sits at 18.3M. The +-2.36% price change was insignificant, leaving IBM's price at $4.55...

The volume for Ardelyx stock increased for one day, resulting in a record-breaking daily growth of 269% of the 65-Day Volume Moving Average

Ardelyx, Inc. (NASDAQ:ARDX  Free Report)  Investment analysts at Wedbush raised their FY2023 earnings estimates for shares of Ardelyx in a research report issued on Wednesday, September...

FY2023 EPS Estimates for Ardelyx, Inc. Raised by Wedbush (NASDAQ:ARDX)

WALTHAM, Mass., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class...

Ardelyx Showcased Encouraging Data on Treatment Satisfaction and Efficacy of IBSRELA  (tenapanor) for IBS-C at GHAPP 2023

Ardelyx, Inc. (NASDAQ:ARDX  Free Report)  Analysts at HC Wainwright issued their Q3 2023 earnings per share (EPS) estimates for Ardelyx in a research note issued on Thursday...

Ardelyx, Inc. Expected to Post Q3 2023 Earnings of ($0.10) Per Share (NASDAQ:ARDX)

Ardelyx, Inc. is a biopharmaceutical company. It engages in the research, development, and commercialization of medicine for the treatment of cardiorenal diseases. Its product portfolio includes tenapanor, which is an experimental medication that works exclusively in the gut and is in late-stage clinical development. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet on October 17, 2007 and is headquartered in Waltham, MA.

Watchers	15,637
52-Wk Low	$1.10
52-Wk High	$5.13

Market Cap	$860.56M
Volume (M)	1.94M
52-Wk High	$5.13
52-Wk Low	$1.10

ARDX Ardelyx Inc

About

Feed

News

Sentiment

Earnings

Fundamentals